Pre-Conference Seminar Day

Explore the Agenda

Pre-Conference Seminar Day

Monday, October 12

Scientific Program Day One

Tuesday, October 13

Scientific Program Day Two

Wednesday, October 14

Post-Conference Workshop Day

Thursday, October 15

Introduction to ADCs Day 4th Novel Conjugates Day 3rd Pharmacology Day 7th Toxicity Day 10th ADCs in Combination Day 2nd Analytical & CQA Day 8th CMC Day

Introduction to ADCs Day

If you’re a new entrant to the ADC field, join the introductory 101 day to brush up on your ADC knowledge ahead of the main scientific program.

David Bramhill

President & Founder, Bramhill Biologics Consulting

John Lambert

Independent Consultant & Honorary Professor, Queens University Belfast

As more companies enter the ever-growing antibody-drug conjugate field, this seminar day will provide you with the critical knowledge gained over years of research that’s culminated in the presently approved ADCs and booming innovation in the field. Led by long-standing experts and KOLs, join this one-stop-shop of ADC learning to establish a core understanding of the essential elements in ADC discovery and early development.

Morning session focus areas include:

Gaining familiarity with the fundamental early learnings that inform ADC design
Learning about the key insights that allowed early investigators to overcome the initial challenges tha hindered early ADC programs
Evaluating payload choices for ADCs
Reviewing linker design chemistry and what it can bring
Understanding the impact of conjugation site selection on ADCs

Lunch & Networking

Afternoon session key learning objectives:

Gaining an understanding of the biological aspects of ADCs
Selecting the most appropriate ADC target
Choosing an optimum antibody format
Analyzing the choices and trade-offs in utilizing the chemistry ADC toolbox
Assessing key factors in the evaluation of efficacy information from in vivo preclinical models

End of Introduction to ADCs Day

4th Novel Conjugates Day

Pushing the Boundary of Novel Bioconjugate Mechanisms & Design

Theme 1: Raising the DAR: Spotlighting Design & Preclinical Profiles of High DAR & Multi-Payload Conjugates

Theme 2: Investigating the Potential of Alternative Payload Mechanisms to Advance Beyond Pan-Cytotoxic ADC Therapies

Theme 3: Stretching the Limits of Traditional ADC Design: Combining Payload & Antibody Innovation on One ADC

Presentation Preview: Best of Both Worlds? Spotlighting Discovery of Bispecific, Dual Payload ADC OBI-221: 2 + 2 = Innovation

Ya-Chi Chen

Chief Scientific Officer, OBI Pharma

Exploring rationale and design of OBI-221, a dual payload bispecific ADC targeting cMET/HER3
Outlining lessons learned from pursuing a two hit, two target approach to guide future ADC innovation opportunities
Evaluating initial characterization of OBI-221, contextualized with early clinical performance of TROP2 ADC leveraging same design principles

3rd Pharmacology Day

Accelerating the Next Wave of Tumor- Targeting Mechanisms & Behavior

Theme 1: Understanding the PD Profiles of Masked Payload & Dual Payload ADCs to Assess Benefit Against Traditional Therapies

Theme 2: Carrying Out Thorough Pharmacology Studies to Understand & Model ADC Mechanisms & Behavior

Theme 3: Highlighting Early Characterization & PD Modeling to De-Risk Preclinical Characterization of Novel ADC Payloads & Design

Presentation Preview: Assessing the Mechanism & PD Characterization of Conditionally Active Biologics Leveraging the TME to Improve ADC Therapeutic Index

Jian Chen

Director - Translational Research & Preclinical Development, BioAtla

Highlighting the benefits and potential of conditionally activated ADCs against traditional conjugate design
Exploring Conditionally Active Biologic mechanism leveraging tumor pH and physiological conditions for ADC activation
Spotlighting PD profiles of conditionally active ADCs to demonstrate improved therapeutic index

7th Toxicity Day

Predicting, Characterizing & Mitigating ADC Toxicities to Widen Therapeutic Index

Theme 1: Expanding the ADC Preclinical Toolbox to Improve Translation of ADC Toxicities to the Clinic

Theme 2: Analyzing Translational Profiles of ADCs Leveraging Rationale-Driven Design to Improve Tolerability & Widen Therapeutic Index

Theme 3: Incorporating the Physician Voice to Understand Mitigation Strategies & Experiences with Clinical Adverse Events

Presentation Preview: Evaluating Strategies to Assess Safety Profile of Novel ADC Payloads Under Accelerated Platform Development

Malini Iyer

Associate Director, Oncology Safety & Discovery, AstraZeneca

Understanding strategies to accelerate development cycle for novel ADC linker-payloads
Defining the importance of safety profiles of novel payloads, contextualized through assessment of free payload versus ADC tolerability comparison
Evaluating in vitro assays to employ for early payload safety profiling leading up to in vivo studies

10th ADCs in Combination Day

Unlocking the Therapeutic Power of Rationale- Driven ADC Combinations

Theme 1: Leveraging the Power of Clinical Combinations to Elevate ADC Patient Impact in Early-Line Oncology Treatment Regiments

Theme 2: Harnessing the Ability of Dual Payload & Combination Therapies to Combat Resistance Mechanisms & Improve Clinical Impact

Theme 3: Laying Out Principles of ADC Combination Parter Selection & Design to Approach Translation with Confidence

Presentation Preview: Utilizing Immune System Interactions & Fc Effector Function Analysis to Rationally Select Optimum ADC Combination Partners

Greg Thurber

Professor of Chemical and Biomedical Engineering, University of Michigan

Leveraging understanding of ADC immune system interactions to unlock clinically relevant checkpoint inhibitor combinations
What are other rationale-driven ADC combination partners in the immuneoncology field?
Deep diving into preclinical Fc effect function to interpret role played in ADC combinations, contextualized with Fc silent versus wild type clinical readouts

2nd Analytical & CQA Day

Elevating Confident Characterization of Increasingly Complex Conjugates

Theme 1: Setting the Scene for ADC CQAs & Understanding Best Approaches to Ensure Product Quality Through Robust Control Strategies

Theme 2: Preparing for the Next Wave: What Analytical Considerations Need to Be Made for Increasingly Complex Conjugates?

Theme 3: Delving Into Best Practices to Confidently Characterize ADC Structural & Physicochemical Properties

Presentation Preview: Evaluating Impurity Qualification Requirements for Drug-Linkers Related Impurities Used to Generate ADCs

Sarah Shi

Director, Regulatory CMC, BeOne Medicines

Evaluating conjugatable impurities in ADC drug-linkers for potential toxicological risks
Drug-linker conjugatable impurities present at ≤1.0% weight/weightare unlikely to pose a risk to patients
Contextualizing how data provides science-based justification to increase qualification limit from 0.15% to 1.0% weight/weightfor DL intermediates

8th CMC Day

Manufacturing Cost Efficient & Regulatory Compliant ADCs at Scale

Theme 1: Leveraging Sponsor-Regulator Interactions & Feedback to Best Meet ADC Regulatory Expectations

Theme 2: Navigating DS & DP CMC & Formulation Intricacies to Streamline Late-Stage ADC Manufacturing

Theme 3: Commercial ADC Manufacturing: Undergoing Process Scale Up & Technology Transfer Without Impacting Product Quality

Presentation Preview: Leveraging Novel Process & Technology Options to Optimize Vial Fogging Challenges in ADC DP Manufacturing

Paritosh Pande

Associate Principal Scientist, Sterile Drug Product Commercialization, Merck & Co.

Highlighting the importance of optimizing container selection and process levers to optimize ADC DP lyophilization
Optimizing ADC DP manufacturing process to reduce challenges with vial fogging through hydrophobic vial technology
Showcasing learnings within ADC manufacturing control strategy

Ambassador’s Reception Hosted By Abzena

The first exclusive networking event at World ADC San Diego. Under the California sunshine, this invitation-only, informal reception is your perfect opportunity to reunite with old friends and meet new colleagues ahead of the main conference days.